 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Ixion Biotechnology, Inc.
 |
Ixion Biotechnology, Inc. |
 |
 |
 |
PROFILE |
 |
Kidneys are at the heart of Ixion Biotechnology. The firm is researching an islet stem-cell therapy to correct diabetes; the islet peptide inhibits insulin. It is also studying how the body processes oxalates, a byproduct of oxalic acid found in some foods; faulty oxalate processing is responsible for kidney stones. Products in development include Ox-Control, a nutritional supplement to help the body process oxalates, and drug candidate IxC1, which may prevent kidney stones. The firm's technology is based on the genes of "Oxalobacter formigenes," a bacteria that can break down oxalates. Sweden-based Q-Med, which makes biologic-based cosmetic implants, owns nearly 60% of Ixion.
COMPETITION |
 |
Alteon Inc. (ALT)
Baxter International Inc. (BAX)
SUGEN, Inc. (dossier)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.40
1-Yr. Sales Growth: 293.4%
Employees: 21
Revenue per employee: $19,047.62
KEY PEOPLE |
 |
Weaver H. Gaines
CEO
David C. Peck
CFO
CONTACT INFO |
 |
13709 Progress Blvd.
Alachua, FL 32615
US
Phone: 904-418-1428
Fax: 904-418-1583
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |